TherapeuticsMD (TXMD) Operating Leases (2019 - 2026)

TherapeuticsMD has reported Operating Leases for 8 years, with the latest figure at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 19.06% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 19.06% YoY), and the FY2025 full-year result was $5.1 million, down 28.61% from the prior year.
• Operating Leases for Q1 2026 stood at $4.8 million, down from $5.1 million in the prior quarter.
• The five-year high for Operating Leases was $7.9 million in Q1 2022, with the low at $4.8 million in Q1 2026.
• Historically, Operating Leases has averaged $6.5 million across 5 years, with a median of $6.7 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Leases rose 9.84% — and 2025, when it dropped 28.61%.
• TherapeuticsMD's Operating Leases stood at $7.4 million in 2022, then declined by 11.36% to $6.5 million in 2023, then gained by 9.84% to $7.2 million in 2024, then retreated by 28.61% to $5.1 million in 2025, then declined by 5.82% to $4.8 million in 2026.
• The last three Operating Leases figures came in at $4.8 million (Q1 2026), $5.1 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.